January 2026 in “GSC Biological and Pharmaceutical Sciences” Adapalene, Diosmin, and Azelastine could be repurposed to treat onchocerciasis.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
2 citations
,
May 2023 in “Journal of Immunotherapy” Sintilimab treatment caused hair loss but led to complete tumor remission.
2 citations
,
January 2025 in “Journal of Clinical Immunology”
August 2013 in “Nature Reviews Drug Discovery” New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
Interest in JAK inhibitors for hair loss increased significantly after media coverage and FDA approval.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
6 citations
,
January 2013 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” A new compound shows promise as a topical treatment for hair loss.
April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
7 citations
,
January 2022 in “SAGE open medical case reports” Upadacitinib successfully treated a child's severe skin and hair loss issues.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
Potassium channel openers like minoxidil boost hair growth.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
18 citations
,
February 2023 in “eLife” ILC1-like cells can independently cause alopecia areata.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
5 citations
,
February 1997 in “Bioorganic & Medicinal Chemistry” New compounds were made that effectively block a specific enzyme related to androgen conditions.
August 2016 in “Journal of Investigative Dermatology” Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
Patients with alopecia areata using Janus kinase inhibitors are not following lab monitoring guidelines.
25 citations
,
April 1985 in “Journal of Investigative Dermatology”
The treatment was ineffective in humans.
March 2026 in “Mendeley Data” Janus kinase inhibitors help hair regrowth in kids with alopecia areata but need more safety research.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology” Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
March 2010 in “Ejc Supplements” Chemotherapy significantly lowers Inhibin A levels in breast cancer patients.
69 citations
,
February 2008 in “The American journal of pathology” Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
Keratinocytes can reduce the survival of certain melanoma cells, suggesting new therapy paths.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” HDAC inhibitors like Vorinostat and Entinostat may encourage hair regrowth and could be new treatments for hair loss conditions.